New imaging test aids Alzheimer's diagnosis

August 23, 2012, Washington University in St. Louis
The image on the left is a PET scan of a normal brain. The image on the right is heavily blackened throughout the cerebral cortex due to the the presence of amyloid plaques. Amyloid is found in the brains of patients with dementia due to Alzheimer’s disease

In research studies, scientists regularly use positron emission tomography (PET) scans to detect signs of Alzheimer's disease. Now, Washington University physicians at Barnes-Jewish Hospital are the first in Missouri to offer a new type of PET scan for patients with memory disorders and other forms of cognitive impairment who are not involved in research studies.

This new imaging test is now available to patients being evaluated for Alzheimer's disease because the U.S. (FDA) recently approved the use of a radioactive diagnostic agent, Amyvid™ (Florbetapir F 18 Injection), for use in a clinical setting.

The agent detects neuritic plaques, a hallmark of Alzheimer's disease, by binding to abnormal deposits of the protein beta-amyloid that develop in the brains of patients with the disorder. This makes the plaques "light up" during a PET scan.

"We're using the scans in patients whose cognitive function is impaired," says Farrokh Dehdashti, MD, professor of radiology in the Division of Nuclear Medicine at the Mallinckrodt Institute of Radiology. "First, the patient sees a neurologist, or other specialist in cognitive disorders, to confirm that a test like this would be appropriate, and then we conduct the to learn whether are present. In that way, the test allows both doctors and patients to have a better idea of whether the patient's is related to Alzheimer's disease or some other illness."

With , nuclear medicine specialists like Dehdashti can now use the diagnostic agent, which has a longer half-life than the compound used in research studies, making it better suited for clinical use. As a single test, PET scans can't confirm Alzheimer's disease, but a negative test that finds no evidence of elevated beta-amyloid can help rule out the disease as the cause for the patient's cognitive impairment.

"What complicates the results of a scan is that although Alzheimer's disease is very common, it's not the only reason that we might detect amyloid," according to Jonathan McConathy, MD, PhD, assistant professor of radiology. "A positive scan could mean that a person has Alzheimer's disease, or it could be related to some other neurologic disorder. It's also possible to find amyloid in the brain of a person who has no symptoms of Alzheimer's disease or other cognitive problems, so a positive test doesn't confirm that someone has the disease."

He says a positive scan indicates only that elevated levels of amyloid are present. But amyloid plaques can accumulate in the brains of people with other types of neurologic problems, such as dementia with Lewy bodies or cerebral amyloid angiopathy. Plaques also can occur in some older adults who are cognitively normal.

"The test should be used in conjunction with other diagnostic evaluations from a neurologist," Dehdashti says. "But when a scan is negative, it's highly unlikely that the cognitive impairment is due to Alzheimer's disease."

"These PET scans have the potential to be really useful as treatments for Alzheimer's are developed," McConathy says. "Once we have treatments to significantly slow down or stop the progression of Alzheimer's , then I think this kind of imaging will become very important in deciding who should be treated and, potentially, whether a treatment is working."

Explore further: Mount Sinai is first in New York state to perform new Alzheimer's imaging test in clinical setting

Related Stories

Mount Sinai is first in New York state to perform new Alzheimer's imaging test in clinical setting

June 20, 2012
The Mount Sinai Medical Center is the first institution in New York State to use in the clinical setting a newly approved imaging technique to detect Alzheimer's disease (AD) in people who are cognitively impaired. Until ...

Alzheimer's plaques in PET brain scans identify future cognitive decline

July 11, 2012
Among patients with mild or no cognitive impairment, brain scans using a new radioactive dye can detect early evidence of Alzheimer's disease that may predict future decline, according to a multi-center study led by researchers ...

Is it Alzheimer's disease or another dementia? Marker may give more accurate diagnosis

November 30, 2011
New research finds a marker used to detect plaque in the brain may help doctors make a more accurate diagnosis between two common types of dementia – Alzheimer's disease and frontotemporal lobar degeneration (FTLD). ...

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.